ClinConnect ClinConnect Logo
Search / Trial NCT06926647

A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B

Launched by BEIJING 302 HOSPITAL · Apr 11, 2025

Trial Information

Current as of July 22, 2025

Not yet recruiting

Keywords

Nucleos(t)ide Analogues(N As) Interferon Alpha(Ifnα)

ClinConnect Summary

This clinical trial is looking at how well different antiviral treatments work for children aged 1 to 12 years who have chronic hepatitis B (a long-lasting infection caused by the hepatitis B virus, or HBV). The study will enroll a total of 2,000 children, including those who have never been treated before (1,600 kids) and those who have been treated (400 kids). The goal is to see which treatments are most effective and safe for these young patients.

To participate, children must meet specific requirements. They should be between 1 and 12 years old, have tested positive for the hepatitis B virus for more than six months, and, for the treatment group, have been on antiviral medication for more than a year. Parents or guardians must provide consent for their child to join, and if the child is 8 years or older, they will need to sign as well. The trial is not yet recruiting participants, but it will provide valuable insights into managing chronic hepatitis B in children, helping doctors make better treatment decisions in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Initial Treatment Group:
  • 1. The guardian understands and signs the informed consent form (both parents must sign), and adheres to the relevant requirements of this study. If the participant is 8 years old or older, they must also sign the informed consent form. For participants under 8 years old who can express consent, their consent must be clearly documented.
  • 2. Age: ≥1 year and \<13 years, either sex;
  • 3. Positive for HBsAg and/or HBV DNA for more than 6 months;
  • 4. No prior antiviral treatment.
  • * Treated Group:
  • 1. The guardian understands and signs the informed consent form (both parents must sign), and adheres to the relevant requirements of this study. If the participant is 8 years old or older, they must also sign the informed consent form. For participants under 8 years old who can express consent, their consent must be clearly documented.
  • 2. Age: ≥3 years and \<13 years, either sex;
  • 3. Previously diagnosed with chronic hepatitis B and received antiviral treatment with NAs for more than 1 year and currently on treatment;
  • 4. No history of IFNα use in the past 6 months;
  • 5. Negative for HBV DNA;
  • 6. HBsAg quantification \<10,000 IU/ml (HBsAg can be negative in the drug discontinuation observation group);
  • 7. The drug discontinuation observation group must also achieve negative HBV DNA and HBeAg seroconversion for at least 1 year (based on continuous results from three consecutive reviews), and HBsAg \<10,000 IU/ml; NAs will be discontinued after enrollment.
  • Exclusion Criteria:
  • 1.In the interferon group, blood white blood cell count \<3.5×10\^9/L, or platelet count \<80×10\^9/L, or prothrombin activity \<60%, or total bilirubin \>34μmol/L, or serum albumin \<35g/L, or serum creatinine \>133μmol/L; 2.Coexistence of other active infections; 3. Coexistence of other chronic liver diseases or active liver diseases, such as autoimmune liver disease, drug-induced liver injury, Wilson's disease, decompensated cirrhosis, liver cancer; 4. Coexistence of other severe systemic diseases or malignant tumors, etc.; 5. History of allergy to nucleoside analogues or interferon; 6. Subjects whom the investigator deems to have poor compliance, unable or unwilling to provide informed consent, or unable to adhere to the study requirements, or other conditions not suitable for participation in this study.

About Beijing 302 Hospital

Beijing 302 Hospital is a leading medical institution in China, renowned for its advanced clinical research and comprehensive healthcare services. As a sponsor of clinical trials, the hospital is committed to advancing medical knowledge and improving patient outcomes through rigorous scientific inquiry and innovation. With a multidisciplinary team of experienced researchers and healthcare professionals, Beijing 302 Hospital focuses on a wide range of therapeutic areas, employing state-of-the-art facilities and methodologies to ensure the highest standards of trial integrity and patient safety. The hospital's dedication to ethical practices and collaboration fosters an environment conducive to groundbreaking research and the development of new treatment modalities.

Locations

Hefei, , China

Nanchang, , China

Shenzhen, , China

Xiamen, , China

Nanning, , China

Dongguan, , China

Foshan, , China

Dalian, , China

Yongcheng, , China

Guangzhou, , China

Shanghai, , China

Xi'an, , China

Luoyang, , China

Nanyang, , China

Guangzhou, , China

Nanchang, , China

Xi'an, , China

Zhongshan, , China

Taiyuan, , China

Xinxiang, , China

Yuncheng, , China

Linfen, , China

Xuchang, , China

Zhumadian, , China

Ankang, , China

ürümqi, , China

Wuhan, , China

Xiamen, , China

Liuzhou, , China

Liaocheng, , China

Shijiazhuang, , China

Beijing, , China

Zhenzhou, , China

Xiamen, , China

Shangqiu, , China

Anyang, , China

Beihai, , China

Binzhou, , China

Changzhi, , China

Changzhou, , China

Chengdu, , China

Chengdu, , China

Dongying, , China

Foshan, , China

Guangzhou, , China

Haikou, , China

Handan, , China

Hepu, , China

Heze, , China

Jiangmen, , China

Lanzhou, , China

Lhasa, , China

Linfen, , China

Longyan, , China

Luzhou, , China

Nanchang, , China

Nanchang, , China

Nanning, , China

Putian, , China

Putian, , China

Qingdao, , China

Quanzhou, , China

Queshan, , China

Shangcheng, , China

Shangqiu, , China

Shangqiu, , China

Shaoguan, , China

Shihezi, , China

Shijiazhuang, , China

Suzhou, , China

Tai'an, , China

Taiyuan, , China

Weifang, , China

Weishi, , China

Xi'an, , China

Xichang, , China

Xining, , China

Xinxiang, , China

Xixian, , China

Xuchang, , China

Yantai, , China

Yulin, , China

Zibo, , China

ürümqi, , China

Patients applied

0 patients applied

Trial Officials

Fusheng Wang

Study Director

Fifth Medical Center of Chinese PLA General Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported